Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry.
Cook G, Liakopoulou E, Pearce R, Cavet J, Morgan GJ, Kirkland K, Lee J, Davies FE, Hall R, Rahemtulla A, Russell N, Marks DI; British Society of Blood & Marrow Transplantation Clinical Trials Committee. Cook G, et al. Among authors: rahemtulla a. Biol Blood Marrow Transplant. 2011 Nov;17(11):1638-45. doi: 10.1016/j.bbmt.2011.04.005. Epub 2011 Apr 23. Biol Blood Marrow Transplant. 2011. PMID: 21565277 Free article.
Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma.
Parrish C, Rahemtulla A, Cavet J, Pearce RM, Kirkland K, Lee J, Cook M, Wilson K, Cook G; Clinical Trials Committee of the British Society for Blood and Marrow Transplantation. Parrish C, et al. Among authors: rahemtulla a. Biol Blood Marrow Transplant. 2015 Jul;21(7):1330-4. doi: 10.1016/j.bbmt.2015.03.026. Epub 2015 Apr 3. Biol Blood Marrow Transplant. 2015. PMID: 25843652 Free article.
The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, Mahendra P, Milligan D, Byrne J, Littlewood T, Fegan C, McQuaker G, Pagliuca A, Johnson P, Rahemtulla A, Morris C, Marks DI; British Society of Blood and Marrow Transplantation. Bird JM, et al. Among authors: rahemtulla a. Br J Haematol. 2006 Aug;134(4):385-90. doi: 10.1111/j.1365-2141.2006.06191.x. Epub 2006 Jul 5. Br J Haematol. 2006. PMID: 16822294 Free article.
Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.
Hunter HM, Peggs K, Powles R, Rahemtulla A, Mahendra P, Cavenagh J, Littlewood T, Potter M, Hunter A, Pagliuca A, Williams CD, Cook G, Towlson K, Marks David I, Russell NH; Clinical Trials Committee of the British Society of Blood and Marrow Transplantation (BSBMT). Hunter HM, et al. Among authors: rahemtulla a. Br J Haematol. 2005 Feb;128(4):496-502. doi: 10.1111/j.1365-2141.2004.05330.x. Br J Haematol. 2005. PMID: 15686458 Free article.
LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ. Perz JB, et al. Among authors: rahemtulla a. Bone Marrow Transplant. 2007 Jan;39(1):41-7. doi: 10.1038/sj.bmt.1705544. Epub 2006 Nov 20. Bone Marrow Transplant. 2007. PMID: 17115062
Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.
Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, Lemoli RM, Rao K, Maris M, Pagliuca A, Uberti J, Scheid C, Noppeney R, Cook G, Bokhari SW, Worel N, Mikala G, Masszi T, Taylor R, Treisman J. Douglas KW, et al. Among authors: rahemtulla a. Bone Marrow Transplant. 2012 Jan;47(1):18-23. doi: 10.1038/bmt.2011.9. Epub 2011 Feb 28. Bone Marrow Transplant. 2012. PMID: 21358693
Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.
Gabriel IH, Sergeant R, Szydlo R, Apperley JF, DeLavallade H, Alsuliman A, Khoder A, Marin D, Kanfer E, Cooper N, Davis J, MacDonald D, Bua M, Foroni L, Giles C, Milojkovic D, Rahemtulla A, Rezvani K. Gabriel IH, et al. Among authors: rahemtulla a. Blood. 2010 Sep 23;116(12):2033-9. doi: 10.1182/blood-2010-03-273706. Epub 2010 Jun 18. Blood. 2010. PMID: 20562327 Free PMC article.
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure.
Rezvani K, Kanfer EJ, Marin D, Gabriel I, Rahemtulla A, Taylor A, Macdonald D, Dazzi F, Milojkovic D, Foroni L, Pavlu J, Sargent J, Le Dieu R, Goldman JM, Apperley J, Szydlo R. Rezvani K, et al. Among authors: rahemtulla a. Biol Blood Marrow Transplant. 2012 Feb;18(2):235-40. doi: 10.1016/j.bbmt.2011.06.010. Epub 2011 Jun 30. Biol Blood Marrow Transplant. 2012. PMID: 21723225 Free article. Clinical Trial.
125 results